AN2 Therapeutics to Present at Upcoming Investor Conferences
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical firm specializing in treatments for severe infectious diseases, announced participation in two investor conferences in November 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical firm specializing in treatments for severe infectious diseases, announced participation in two investor conferences in November 2022. The Stifel 2022 Healthcare Conference will take place from November 15-17 in New York, where CEO Eric Easom will present on November 16 at 9:10 a.m. ET. Additionally, Easom will join a fireside chat at the 5th Annual Evercore ISI HealthConX Conference on November 30 at 2:15 p.m. ET. Webcasts for both events will be accessible on the company’s website.
Details
News Market Reaction – ANTX
The recorded move for ANTX in the trading session of this news was +6.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in November.
Details of the events are as follows:
Stifel 2022 Healthcare Conference, November 15-17, 2022, New York, New York.
- Eric Easom, Co-Founder, President and CEO will present a corporate overview on Wednesday, November 16 at 9:10 a.m. ET.
5th Annual Evercore ISI HealthConX Conference (virtual).
- Eric Easom, Co-Founder, President and CEO will participate in a fireside chat on Wednesday, November 30 at 2:15 p.m ET.
Webcasts can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation and fireside chat.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our lead candidate is epetraborole, which we are studying in a pivotal Phase 2/3 trial as a once-daily, oral treatment with a novel mechanism of action for patients with NTM lung disease, a rare, chronic, and progressive infectious disease caused by bacteria, known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at www.an2therapeutics.com.
COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com
INVESTOR AND MEDIA CONTACT:
Anne Bowdidge
ir@an2therapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.